Study of BEST1 Vitelliform Macular Dystrophy

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorColumbia University

About this trial

The purpose of this study is to establish the natural history of of participants with BESTROPHIN 1 Vitelliform Macular Dystrophy.

The blinding disorder Best Vitelliform Macular Dystrophy (VMD) is caused by any one of more than 250 different mutations in the BEST1 gene.

As new treatments are developed, a clear understanding of the natural history of disease progression of BEST1 VMD is necessary. The goals of this natural history study are to:

1. Report the natural history of retinal degeneration in participants with a clinical diagnosis of VMD with molecular confirmation of a pathogenic BEST1 mutation(s). 2. Identify sensitive structural and functional outcome measures to use for future multicenter clinical trials for the treatment of BESTROPHIN 1 VMD. 3. Compare progression of the identified structural and functional measures between the two eyes to judge the suitability of the second untreated eye as a control for a future clinical trial involving unilateral treatment 4. Identify well-defined patient populations for future clinical trials of investigative treatments for BEST1 VMD.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Ability to provide informed consent

Diagnosis of BEST1-associated VMD by study physician, who are trained retinal specialists in the university clinic Must be able to commit to 4 follow-up study visits (3 years)

Disqualifiers

Systemic condition that prevents the participant from undergoing the exams

Trial population

Patients are expected to present to the clinic at all age groups; enrollment of subjects \<18 years of age will be obtained by informed consent in the company of a parent or legal guardian. There will also be no gender-or ethnic/racial specific inclusion criteria. The enrollment of non-English speaking subjects is not expected.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Natural History Study

    Other intervention

    Longitudinal assessment of participants with BEST1 Vitelliform Macular Dystrophy

Treatment groups

52 Participants
are divided into 1 treatment group
Group A: Best Vitelliform Macular Dystrophy (VMD) Participants1 intervention

Trial outcomes

Primary outcomes

1

Medmont Dark Adapted Chromatic (DAC) Automated Perimeter

Time frame
Up to 3 years
2

Full-field electroretinogram (ERG)

ERG conducted under International Society for Clinical Electrophysiology of Vision (ISCEV) Protocol.

Time frame
Up to 3 years
3

Electroocoulogram (EOG)

EOG conducted under International Society for Clinical Electrophysiology of Vision (ISCEV) Protocol

Time frame
Up to 3 years
4

Optical Coherence Tomography (OCT)

Time frame
Up to 3 years

Secondary outcomes

1

Best-corrected Visual Acuity (BCVA)

Time frame
Up to 3 years
2

Color Fundus Photos

Time frame
Up to 3 years
3

Macular Integrity Assessment (MAIA) Microperimetry

Time frame
Up to 3 years
4

Goldman Kinetic Visual Field

Time frame
Up to 3 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Columbia University

Lead sponsor

Universität Tübingen

Collaborator

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts

Collaborator

National Eye Institute (NEI)

Collaborator